Trial Profile
A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for phase III development in postmenopausal osteoporosis, and the offset of effect on biomarkers and BMD [EXTENSION OF 700004435]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2021
Price :
$35
*
At a glance
- Drugs Balicatib (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Novartis
- 20 Nov 2013 New trial record